Entrada Therapeutics, Inc. (TRDA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
6 Tide Street
Boston, MA 02210
United States of America (the)
Phone
857 520 9158
Website
Sector
Healthcare
Industry
Biotechnology
Employees
183
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Dipal Doshi | Chief Executive Officer & Director | 998,250 | 1976 |
| Nathan J. Dowden | President & Chief Operating Officer | 737,182 | 1971 |
| Natarajan Sethuraman | President of Research & Development | 768,000 | 1962 |
| Karla MacDonald | Chief Corporate Affairs Officer | 0 | N/A |
| Sandeep Basnet | Head of Information Technology | 0 | N/A |
| Kerry Robert | Senior Vice President of People | 0 | N/A |
| Kevin Healy | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Kory James Wentworth | Chief Financial Officer & Treasurer | 0 | 1979 |
| Jared Cohen | General Counsel | 0 | N/A |
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.